title: Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports.
abstract: The long-term efficacy and safety of deep brain stimulation (DBS) implant for Parkinson's disease (PD) is described in several recent papers. This procedure has been reported to permit a stable reduction of dopaminergic therapy requirements for up to 5 years, although some expectation of deterioration in non-dopaminergic signs has been recently stated. Our aim is to perform a literature-based review of papers available describing long-term post-operative follow-up after a bilateral implant for subthalamic DBS (STN-DBS). Only peer-reviewed published papers with a post-operative follow-up of at least 5 years were considered. Clinical outcome, disease progression and side effects were assessed at baseline and 2 (or 3 years) and 5 years after surgery. Seven papers were included in the review. A total of 238 patients were analyzed. STN-DBS was confirmed to be an effective treatment for selected patients with PD. In all studies, off-related motor symptoms improved dramatically, compared with pre-implant, at 2 (or 3, according to the study) years and this result persisted at 5-year evaluations. Antiparkinsonian drug reductions, improvements in motor fluctuations and dyskinesias, functional measures and the progression of underlying PD were also reported in all series. Some axial scores, in particular postural stability and speech, improved transiently. Persisting adverse effects included eyelid opening apraxia, weight gain, psychiatric disorders, depression, dysarthria, dyskinesias, and apathy. The present review of the 5-year observations confirms that STN-DBS is a powerful method in the management of PD, but its long-term effects must be thoroughly assessed.
authors.affiliation: Università Cattolica del Sacro Cuore, Milan, Italy. luigiromito@istituto-besta.it
authors.forename: Luigi M
authors.initials: LM
authors.lastname: Romito
authors.forename: Alberto
authors.initials: A
authors.lastname: Albanese
mesh_terms: D046690:Deep Brain Stimulation / Q000295:instrumentation / Q000379:methods* / Q000639:trends*; D015259:Dopamine Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004567:Electrodes, Implanted / Q000592:standards* / Q000639:trends; D006801:Humans; D010300:Parkinson Disease / Q000503:physiopathology / Q000628:therapy*; D020531:Subthalamic Nucleus / Q000502:physiology / Q000601:surgery*
chemical_list: D015259:Dopamine Agents